OrsoBio to Present Preclinical and Clinical Data from Its Mitochondrial Protonophore Portfolio at ADA 2026 Scientific Sessions
OrsoBio, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for obesity and related metabolic disorders, has announced a series of new clinical and preclinical findings that will be presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA), held June 5–8, 2026, in New Orleans, Louisiana. The data package highlights the therapeutic potential of mitochondrial protonophores as a differentiated metabolic strategy with multi-system benefits extending beyond traditional weight loss endpoints.
The presentations include clinical results from a Phase 2a study evaluating TLC-6740 in combination with tirzepatide in individuals living with obesity without diabetes (NCT05822544), as well as two preclinical studies of TLC-1180, a second-generation oral mitochondrial protonophore developed to enhance potency and systemic exposure. Together, these findings reinforce OrsoBio’s hypothesis that modulating cellular energy expenditure through mitochondrial mechanisms may provide broad therapeutic benefits across metabolic, cardiovascular, and neurocognitive domains.
Phase 2a Clinical Data: TLC-6740 Combined with Tirzepatide
The centerpiece of OrsoBio’s ADA 2026 presentation is a randomized, double-blind, placebo-controlled Phase 2a clinical study assessing the safety and efficacy of once-daily oral TLC-6740 (180 mg) in combination with the GLP-1/GIP receptor agonist tirzepatide (5 mg weekly subcutaneous injection). The study enrolled participants with obesity who did not have diabetes and followed them for 24 weeks.
At week 24, the combination of TLC-6740 plus tirzepatide demonstrated a statistically meaningful increase in weight loss compared with tirzepatide monotherapy alone. Patients receiving the combination achieved an additional mean weight reduction of 4.5%, suggesting that TLC-6740 may provide additive metabolic benefits when paired with incretin-based therapies.
Beyond weight reduction, the combination therapy also produced improvements across several clinically relevant metabolic endpoints. These included enhanced insulin sensitivity, improved liver health markers, and favorable changes in body composition. Importantly, the improvements in body composition suggest that the weight loss observed may be accompanied by a more favorable ratio of fat loss to lean mass preservation, a growing priority in modern obesity treatment.
Safety and tolerability outcomes were also consistent with prior clinical experience for TLC-6740. The compound was generally well tolerated when administered in combination with tirzepatide. Adverse event rates, including gastrointestinal side effects commonly associated with incretin-based therapies, were comparable between the combination and monotherapy groups. Notably, there were no reports of Grade 3 or severe adverse events, no treatment discontinuations related to safety, and no signs of excessive systemic mitochondrial uncoupling, such as fever or hypermetabolic complications, in participants receiving TLC-6740.
These results support the hypothesis that mitochondrial protonophores may be safely combined with incretin therapies to enhance metabolic outcomes without exacerbating tolerability concerns commonly associated with weight-loss treatments.
Mechanistic Rationale: Energy Intake vs Energy Expenditure
OrsoBio’s clinical program is built on a mechanistic distinction between incretin-based therapies and mitochondrial protonophore-based approaches. While GLP-1 and dual incretin agonists primarily reduce energy intake by suppressing appetite and improving glycemic control, mitochondrial protonophores are designed to increase cellular energy expenditure by mildly uncoupling mitochondrial respiration.
According to the company, this complementary mechanism may allow for synergistic metabolic effects when both pathways are targeted simultaneously. By combining reduced caloric intake with increased energy expenditure, the therapeutic strategy may amplify weight loss and improve downstream metabolic outcomes such as insulin sensitivity and hepatic function.
“Much as advances in incretin biology transformed our understanding of obesity treatment, we believe targeting cellular energy expenditure through mitochondrial protonophores may unlock broad benefits across metabolic, cardiovascular, and neurocognitive health in people living with obesity,” said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. “The consistency of these findings across clinical and preclinical studies strengthens our confidence in the promise of mitochondrial protonophores as a potential new therapeutic class.”
TLC-1180 Preclinical Program: Second-Generation Protonophore
In addition to the clinical data, OrsoBio will present two preclinical abstracts on TLC-1180, a next-generation mitochondrial protonophore designed for improved potency, oral bioavailability, and broader systemic distribution compared with TLC-6740. The compound is currently being evaluated in a Phase 1 clinical trial (NCT07300189) assessing safety, tolerability, and pharmacokinetics.
In diet-induced obese (DIO) mouse models, TLC-1180 demonstrated robust metabolic activity across multiple organ systems. Treatment led to increased energy expenditure and fat-selective weight loss while preserving lean body mass. Importantly, TLC-1180 significantly improved insulin sensitivity across key metabolic tissues, including the liver, skeletal muscle, white adipose tissue (WAT), and heart.
Overall, the compound produced a 140% improvement in whole-body insulin sensitivity compared with control groups. These findings suggest a broad systemic effect on metabolic regulation, extending beyond adipose tissue to include organs critical for glucose homeostasis and cardiovascular function.
TLC-1180 also demonstrated improvements in cardiac metabolic performance and exercise capacity. Treated animals showed longer exercise duration and increased running speed, indicating enhanced physical performance and endurance. These effects suggest potential relevance for obesity-associated cardiovascular conditions, including heart failure with preserved ejection fraction (HFpEF), where metabolic dysfunction plays a key role in disease progression.
“Our clinical findings further support the potential of mitochondrial protonophores as complementary therapies that increase energy expenditure while incretin-based medicines primarily target energy intake,” said Rob Myers, MD, Chief Medical Officer of OrsoBio. “The additive metabolic benefits and favorable safety profile observed with TLC-6740 and tirzepatide validate findings previously seen in preclinical studies and reinforce the potential of this mechanism as both a combination partner and a standalone therapeutic approach in obesity.”
Neurocognitive Findings: Obesity-Associated Cognitive Decline
A second preclinical study of TLC-1180 explored its potential effects on obesity-associated cognitive impairment, an increasingly recognized complication of metabolic disease. Chronic exposure to high-fat and high-sucrose diets in mice is known to induce not only metabolic dysfunction but also impairments in cognition, memory, and exploratory behavior.
In this study, TLC-1180 treatment in diet-induced obese mice led to reductions in body weight, improved glucose tolerance, and decreased hyperinsulinemia. More notably, the compound partially restored cognitive function, including improvements in exploratory behavior and recognition memory tasks.
At the neurobiological level, these behavioral improvements were associated with restored neuronal activation in thalamic brain regions implicated in cognitive processing. Neuronal activity in treated animals returned to levels comparable to those observed in lean control mice, suggesting a potential reversal of obesity-related neural dysfunction.
These findings support the hypothesis that improving systemic metabolic health through mitochondrial mechanisms may also confer neuroprotective benefits. If translated to humans, this could position mitochondrial protonophores as potential therapeutic candidates for addressing cognitive decline associated with obesity and metabolic syndrome.
Broader Implications and Future Development
Collectively, the clinical and preclinical data presented at ADA 2026 suggest that mitochondrial protonophores may represent a new class of metabolic therapeutics capable of addressing multiple dimensions of obesity-related disease. Unlike traditional approaches focused primarily on weight reduction, OrsoBio’s strategy emphasizes systemic metabolic reprogramming across energy balance, insulin sensitivity, cardiovascular function, and cognitive health.
The ongoing development of TLC-1180 in Phase 1 clinical trials will further evaluate the safety profile and pharmacological characteristics of this second-generation compound, while the Phase 2a results for TLC-6740 provide early clinical validation for combination strategies involving incretin-based therapies.
As obesity continues to be a major global health challenge associated with a wide spectrum of comorbidities, including type 2 diabetes, cardiovascular disease, liver disease, and neurocognitive decline, the need for multi-mechanistic therapeutic approaches remains significant. OrsoBio’s mitochondrial protonophore platform represents an emerging effort to address these interconnected disease pathways through a unified metabolic mechanism centered on energy expenditure modulation.
About TLC-6740
TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for obesity and related metabolic diseases, including diabetes and MASH. By increasing energy expenditure through targeted hepatic activity, TLC-6740 is designed to drive weight loss and improve metabolic health, including insulin sensitivity and lipid metabolism. In a Phase 2a trial in individuals with obesity, TLC-6740 combined with tirzepatide resulted in an average of 4.5% greater weight loss compared with tirzepatide alone, with no additional safety concerns, discontinuations, or weight loss plateau at 24 weeks, and improvements across multiple metabolic measures (NCT05822544).
About TLC-1180
TLC-1180 is a novel, potent, oral, mitochondrial protonophore with liver-biased distribution that increases energy expenditure and promotes fat-selective weight loss. In preclinical studies of obese mice and non-human primates, TLC-1180 reduced fat mass, improved glucose control and insulin sensitivity, increased exercise capacity, and mitigated cognitive decline associated with obesity, while also enhancing the efficacy of GLP-1 receptor agonists. TLC-1180 is currently being evaluated in a first-in-human, Phase 1 study (NCT07300189).
About OrsoBio, Inc.
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
